Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolgolimab in MSI/dMMR Colorectal Cancer
NCT06428487Phase 2Completed
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of prolgolimab in colorectal cancer (CRC), sponsored by N.N. Blokhin Russian Cancer Research Center. Started Mar 2022; status: completed.
02
Drugs
prolgolimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06428487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428487.